Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06736470 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Surgical Suction Aspirates Fluorescence Measurement

Study acronym: ATM GBM
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 16, 2024 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Minor Study First Submitted
1,251 trials monitored
See 88 trials at risk
Gliomas are tumors that occur in all ages; they include the most common malign primary central nervous system tumors in developed countries. Gliomas are often aggressive, and their recommended treatment is surgical resection and chemoradiation. Complete tumor removal is challenging because of diffuse cell growth and the proximity of functionally critical tissues. Surgeons use 5-aminolevulinic acid (5-ALA) drug-induced fluorescence to visually detect tumor cells, which improves resection rates and delays tumor progression. Tumor cells are often left unnoticed because of visual obstacles or weak fluorescence, which may lead to local recurrence and reoperations. Surgical suction devices are used to remove cancerous tissues, but so far the suction aspirate tissues have not been routinely used in tissue detection. This single-center observational study compares experts' visual detection of 5-ALA-induced fluorescence and fluorescence detected from the surgical suction waste. The fluorescence from the suction waste will not be reported back to the surgeon.
Trial Details
NCT Number NCT06736470
Lead Sponsor Kuopio University Hospital
Collaborators: Marginum Ltd.
Conditions
(from sponsor)
Gliomas, High-grade Glioma
Related terms Glioma
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov